Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Pozelimab Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentHealthSpringPolicy RX501.182

    Pozelimab-bbfg

    Customize your policy alerts

    Sign up for healthspring Policy RX501.182 alerts

    Get alerted when Policy RX501.182 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    HealthSpring coverage of pozelimab-bbfg (Veopoz) for adult and pediatric members age 1 year and older with CD55-deficient protein-losing enteropathy (CHAPLE disease), subject to specified genetic, laboratory, and symptom criteria.

    Policy Summary
    PayerHealthSpring
    PolicyPozelimab-bbfg
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming age 1 year or older, CHAPLE disease, required genetic and albumin findings, and at least one recent qualifying symptom.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1+Minimum age
    ≤3.2 g/dLSerum albumin threshold
    1 of 4Recent qualifying symptoms
    UnprovenOther indications
    2Vaccine categories
    Policy Summary
    PayerHealthSpring
    PolicyPozelimab-bbfg
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming age 1 year or older, CHAPLE disease, required genetic and albumin findings, and at least one recent qualifying symptom.
    SourceLink
    On This Page
    Medical Necessity and Coverage DeterminationsBilling and Clinical Coding RequirementsAuthorization, Documentation, and Coverage RisksTherapy and Disease OverviewClinical DefinitionsInitial CHAPLE Disease Therapy

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 weeks
    Vaccination interval

    Medical Necessity and Coverage Determinations

    Medically Necessary CHAPLE Disease Treatment

    Pozelimab-bbfg (Veopoz™) may be considered medically necessary for the treatment of CHAPLE disease when ALL of the following criteria are met:

    ALL of the following

    • The individual is an adult or pediatric patient 1 year of age or older.
    • The individual has CD-55 deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.
    • The individual has a clinical history of PLE and genetic testing confirming a biallelic CD55 loss-of-function mutation detected by genotype analysis.
    • The individual has hypoalbuminemia, with a serum albumin concentration of ≤ 3.2 g/dL.≤ 3.2 g/dL
    • ONE or more of the following signs or symptoms within the last six months

      • Abdominal pain
      • Diarrhea
      • Peripheral edema
      • Facial edema

    Pozelimab-bbfg (Veopoz™) is contraindicated in individuals with an unresolved Neisseria meningitidis infection.

    Complement inhibitors, including pozelimab-bbfg, increase susceptibility to serious and life-threatening meningococcal infections, including septicemia and/or meningitis caused by any serogroup, including non-groupable strains.

    Pozelimab-bbfg (Veopoz) is considered experimental, investigational, and/or unproven for all other non-U.S. Food and Drug Administration-approved indications.

    Any use of pozelimab-bbfg (Veopoz) outside the U.S. Food and Drug Administration-approved CHAPLE disease indication described above is considered experimental, investigational, and/or unproven.

    Billing and Clinical Coding Requirements

    HCPCS CodesHCPCS
    J9376HCPCS code listed for pozelimab-bbfg (Veopoz)
    Serum albumin
    Required measureSerum albumin concentration
    Required threshold≤ 3.2 g/dL
    Clinical findingHypoalbuminemia
    Qualifying symptoms
    Minimum requirementAt least one qualifying sign or symptom
    TimeframeWithin the last six months
    Qualifying symptomsAbdominal pain, diarrhea, peripheral edema, or facial edema

    Authorization, Documentation, and Coverage Risks

    Prior Authorization

    CHAPLE Disease Authorization

    Prior authorization may be considered for pozelimab-bbfg (Veopoz™) for adult and pediatric patients 1 year of age or older with CD55-deficient protein-losing enteropathy (CHAPLE disease), when the clinical criteria are met.

    • Indication: CD55-deficient protein-losing enteropathy, also known as CHAPLE disease.
    • Patient must be at least 1 year old.
    Documentation Required

    Required Clinical Documentation

    Submit documentation supporting the diagnosis and medical necessity for Veopoz, including the required clinical history, genetic confirmation, laboratory findings, and current symptoms.

    • Clinical history of protein-losing enteropathy (PLE).
    • Genetic testing confirming a biallelic CD55 loss-of-function mutation by genotype analysis.

    Therapy and Disease Overview

    Pozelimab-bbfg (Veopoz) is a complement inhibitor used to treat CD55-deficient protein-losing enteropathy, also known as CHAPLE disease. HealthSpring may consider coverage medically necessary for adult and pediatric individuals age 1 year and older when the member has a clinical history of protein-losing enteropathy, genetic testing confirms a biallelic CD55 loss-of-function mutation by genotype analysis, serum albumin is ≤ 3.2 g/dL, and at least one qualifying sign or symptom—abdominal pain, diarrhea, peripheral edema, or facial edema—has occurred within the last six months. Because complement inhibition increases susceptibility to serious and potentially fatal meningococcal infection, unresolved Neisseria meningitidis infection is a contraindication.

    Clinical Definitions

    CHAPLE disease
    DefinitionCD55-deficient protein-losing enteropathy
    Also known asCHAPLE disease
    Coverage relationshipThe condition for which pozelimab-bbfg may be medically necessary when policy criteria are satisfied
    Biallelic CD55 loss-of-function mutation
    Genetic findingBoth copies of the CD55 gene have loss-of-function mutations
    Confirmation methodGenotype analysis
    Documentation requirementGenetic testing must confirm the biallelic mutation

    Initial CHAPLE Disease Therapy

    Initial CHAPLE Disease Therapy

    Initial treatment may be considered medically necessary for adults and pediatric individuals age 1 year and older when all of the following are met.

    Initial therapy criteria

    • Eligible age

      • Adult patient: The individual is an adult.
      • Pediatric patient: The individual is a pediatric patient at least 1 year of age.≥ 1 year
    • CHAPLE disease confirmation

    Serum albumin for active CD55-deficient PLE
    Condition assessedActive CD55-deficient protein-losing enteropathy
    Serum albumin threshold≤ 3.2 g/dL
    Additional requirementAt least one qualifying sign or symptom within the last six months
    Active disease symptom requirement
    Required symptomsAt least one of abdominal pain, diarrhea, peripheral edema, or facial edema
    TimeframeWithin the last six months
    Disease statusActive CD55-deficient protein-losing enteropathy
  1. Hypoalbuminemia with serum albumin concentration ≤ 3.2 g/dL.
  2. At least one sign or symptom within the prior six months: abdominal pain, diarrhea, peripheral edema, or facial edema.
  3. Prior Authorization

    Meningococcal Vaccination Required Before First Dose

    Before the first dose of Veopoz, vaccinate the patient against meningococcal infection in accordance with current ACIP recommendations for patients receiving a complement inhibitor.

    • Vaccination must cover serogroups A, C, W, and Y and serogroup B.
    • Administer vaccination at least 2 weeks before the first dose of Veopoz.
    Denial Risk

    Contraindicated Infection

    Veopoz is contraindicated in patients with an unresolved Neisseria meningitidis infection. Treatment in this circumstance presents a coverage and patient-safety risk because complement inhibition increases susceptibility to serious and life-threatening meningococcal infection.

    • Do not initiate or continue treatment while an unresolved Neisseria meningitidis infection is present.
    • Risk includes meningococcal septicemia and/or meningitis caused by any serogroup, including nongroupable strains.
    Denial Risk

    Unapproved Indications

    Veopoz is not medically necessary for indications other than the FDA-approved treatment of CD55-deficient protein-losing enteropathy (CHAPLE disease) in patients meeting the policy criteria.

    • Coverage may be denied for all other non-U.S. FDA-approved indications.
    Denial Risk

    Non-Approved Indication

    Use of pozelimab-bbfg for a non-U.S. FDA-approved indication is considered experimental, investigational, and/or unproven and is not eligible for coverage under this policy.

    • This classification applies to indications outside the FDA-approved CHAPLE disease indication.
    Protein-losing enteropathy (PLE)
    DefinitionExcessive loss of proteins through the gastrointestinal tract
    Clinical contextPLE can occur in many clinical conditions
    When to suspectIn individuals with low serum proteins after other causes of hypoproteinemia have been ruled out
    CHAPLE disease
    Acronym expansionComplement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy
    Alternate nameCD55-deficient protein-losing enteropathy
    ConditionCHAPLE disease
    Active CD55-deficient PLE
    Study definitionActive CD55-deficient protein-losing enteropathy
    Serum albumin criterion≤ 3.2 g/dL
    Symptom criterionAt least one of abdominal pain, diarrhea, peripheral edema, or facial edema within the preceding six months
    CHAPLE disease
    Concise definitionCD-55 deficient protein-losing enteropathy
    Also known asCHAPLE disease
    Covered populationAdult and pediatric individuals 1 year of age and older when clinical criteria are met
    The individual has a clinical history of protein-losing enteropathy.
  4. Genetic testing confirms a biallelic CD55 loss-of-function mutation detected by genotype analysis.
  5. Hypoalbuminemia: Serum albumin concentration is at or below 3.2 g/dL.≤ 3.2 g/dL
  6. Active disease symptoms

    • Abdominal pain within the last six months.
    • Diarrhea within the last six months.
    • Peripheral edema within the last six months.
    • Facial edema within the last six months.